{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:28:37Z","timestamp":1788283717954,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Dutch Research Council","doi-asserted-by":"publisher","award":["NWA.1160.18.038"],"award-info":[{"award-number":["NWA.1160.18.038"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.rpth.2025.103275","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T08:02:09Z","timestamp":1764662529000},"page":"103275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Health care resources and costs associated with delivering gene therapy for hemophilia in clinical practice"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5289-0394","authenticated-orcid":false,"given":"Diaz M.","family":"Prameyllawati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline M.A.","family":"Mussert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn A.H.","family":"Oude Voshaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester F.","family":"Lingsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjon H.","family":"Cnossen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel","family":"Coppens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"van der Valk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank W.G.","family":"Leebeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2638-8045","authenticated-orcid":false,"given":"Renske M.T.","family":"ten Ham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2025.103275_bib1","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3324\/haematol.2019.221093","article-title":"Hemophilia A and B: molecular and clinical similarities and differences","volume":"104","author":"Castaman","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2025.103275_bib2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12929-021-00760-4","article-title":"Advances in the management of haemophilia: emerging treatments and their mechanisms","volume":"28","author":"Okaygoun","year":"2021","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.rpth.2025.103275_bib3","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1007\/s00277-020-04250-9","article-title":"Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting","volume":"99","author":"Ay","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.rpth.2025.103275_bib4","series-title":"Nederlandse Vereniging van Hemofiliebehandelaars","year":"2022"},{"key":"10.1016\/j.rpth.2025.103275_bib5","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0140-6736(20)32722-7","article-title":"The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing","volume":"397","author":"Mancuso","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2025.103275_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102640","article-title":"Gene therapy in hemophilia: the dawn of a new era","volume":"9","author":"Gualtierotti","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103275_bib7","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000679","article-title":"Modeling benefits, costs, and affordability of a novel gene therapy in hemophilia A","volume":"6","author":"Ten Ham","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.rpth.2025.103275_bib8","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/blood.2019003777","article-title":"Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues","volume":"138","author":"Leebeek","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.103275_bib9","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/hematology.2022000388","article-title":"Gene therapy for hemophilia","volume":"2022","author":"Nathwani","year":"2022","journal-title":"Hematology Am Soc Hematol Educ"},{"key":"10.1016\/j.rpth.2025.103275_bib10","doi-asserted-by":"crossref","DOI":"10.1177\/20406207231202306","article-title":"Infrastructural considerations of implementing gene therapy for hemophilia in the Nordic context","volume":"14","author":"Astermark","year":"2023","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.rpth.2025.103275_bib11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/hae.15125","article-title":"UKHCDO gene therapy taskforce: guidance for implementation of haemophilia gene therapy into routine clinical practice for adults","volume":"31","author":"Chowdary","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103275_bib12","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1111\/hae.14867","article-title":"Delivery of gene therapy in haemophilia treatment centres in the United States: practical aspects of preparedness and implementation","volume":"29","author":"Pipe","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103275_bib13","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/hae.14420","article-title":"Delivery of AAV-based gene therapy through haemophilia centres-A need for re-evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC","volume":"27","author":"Miesbach","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103275_bib14","series-title":"Summary of Product Characteristics Roctavian","year":"2023"},{"key":"10.1016\/j.rpth.2025.103275_bib15","series-title":"Summary of Product Characteristics Hemgenix","year":"2023"},{"key":"10.1016\/j.rpth.2025.103275_bib16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s41669-024-00480-z","article-title":"Cost-effectiveness analysis of etranacogene dezaparvovec versus extended half-life prophylaxis for moderate-to-severe haemophilia B in Germany","volume":"8","author":"Meier","year":"2024","journal-title":"Pharmacoecon Open"},{"key":"10.1016\/j.rpth.2025.103275_bib17","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1182\/blood.2021010864","article-title":"The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspective","volume":"138","author":"Bolous","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.103275_bib18","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/13696998.2020.1721508","article-title":"Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A","volume":"23","author":"Cook","year":"2020","journal-title":"J Med Econ"},{"key":"10.1016\/j.rpth.2025.103275_bib19","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/bloodadvances.2018021345","article-title":"Gene therapy in hemophilia A: a cost-effectiveness analysis","volume":"2","author":"Machin","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2025.103275_bib20","series-title":"Valoctocogene Roxaparvovec and Emicizumab for Hemophilia A without Inhibitors: Effectiveness and Value","year":"2020"},{"key":"10.1016\/j.rpth.2025.103275_bib21","first-page":"674","article-title":"Gene therapy may not be as expensive as people think: challenges in assessing the value of single and short-term therapies","volume":"27","author":"Garrison","year":"2021","journal-title":"J Manag Care Spec Farm"},{"issue":"Suppl 2","key":"10.1016\/j.rpth.2025.103275_bib22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/hae.14425","article-title":"International Haemophilia Access Strategy C. Alternative payment models for durable and potentially curative therapies: the case of gene therapy for haemophilia A","volume":"28","author":"Goodman","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103275_bib23","series-title":"Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients With Residual FVIII Levels \u2264 1 IU\/dL Receiving Prophylactic FVIII Infusions","year":"2021"},{"key":"10.1016\/j.rpth.2025.103275_bib24","year":"2021"},{"key":"10.1016\/j.rpth.2025.103275_bib25","year":"2022","journal-title":"CSL Behring"},{"key":"10.1016\/j.rpth.2025.103275_bib26","series-title":"Choosing the best treatment. Decision making in health and medicine","first-page":"53","author":"Hunink","year":"2014"},{"key":"10.1016\/j.rpth.2025.103275_bib27","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1186\/s12913-023-10411-z","article-title":"Is it possible to automate the discovery of process maps for the time-driven activity-based costing method? A systematic review","volume":"23","author":"Iachecen","year":"2023","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.rpth.2025.103275_bib28","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1007\/s11135-017-0574-8","article-title":"Saturation in qualitative research: exploring its conceptualization and operationalization","volume":"52","author":"Saunders","year":"2018","journal-title":"Qual Quant"},{"key":"10.1016\/j.rpth.2025.103275_bib29","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1188\/14.ONF.545-547","article-title":"The use of triangulation in qualitative research","volume":"41","author":"Carter","year":"2014","journal-title":"Oncol Nurs Forum"},{"key":"10.1016\/j.rpth.2025.103275_bib30","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1055\/s-0038-1672208","article-title":"Activity-based costing","volume":"32","author":"Jalalabadi","year":"2018","journal-title":"Semin Plast Surg"},{"key":"10.1016\/j.rpth.2025.103275_bib31","series-title":"Costing manual: methods and reference prices for economic evaluations in healthcare","author":"Roijen","year":"2024"},{"key":"10.1016\/j.rpth.2025.103275_bib32","series-title":"DBC product-finder for tariffs","year":"2024"},{"key":"10.1016\/j.rpth.2025.103275_bib33","series-title":"Gene therapy, environmental safety officer rate. [in Dutch]. Internal report","author":"Kempen","year":"2024"},{"key":"10.1016\/j.rpth.2025.103275_bib34","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/CAD.0000000000000648","article-title":"Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands","volume":"29","author":"Franken","year":"2018","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.rpth.2025.103275_bib35","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.clinthera.2017.05.342","article-title":"Microcosting study of rituximab subcutaneous injection versus intravenous infusion","volume":"39","author":"Mihajlovic","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.rpth.2025.103275_bib36","series-title":"Drug costs in the Netherlands. [in Dutch]","year":"2024"},{"key":"10.1016\/j.rpth.2025.103275_bib37","series-title":"Purchasing power parities","year":"2023"},{"key":"10.1016\/j.rpth.2025.103275_bib38","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.103275_bib39","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.103275_bib40","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5\u2013human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.103275_bib41","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N Engl J Med"},{"issue":"Suppl 6","key":"10.1016\/j.rpth.2025.103275_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia, 3rd ed","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103275_bib43","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/hae.14887","article-title":"Accreditation model of European Haemophilia Centres in the era of novel treatments and gene therapy","volume":"29","author":"Boban","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103275_bib44","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/hae.14709","article-title":"Laying the foundations for gene therapy in Italy for patients with haemophilia A: A Delphi consensus study","volume":"29","author":"Castaman","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103275_bib45","first-page":"196","article-title":"[Gene therapy of Hemophilia: Recommendations from the German, Austrian, and Swiss Society for Thrombosis and Haemostasis Research (GTH)]","volume":"43","author":"Miesbach","year":"2023","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.rpth.2025.103275_bib46","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/hae.14309","article-title":"Evolution of haemophilia integrated care in the era of gene therapy: Treatment centre's readiness in United States and EU","volume":"27","author":"Miesbach","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103275_bib47","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jtha.2022.12.027","article-title":"The ethics of gene therapy for hemophilia: a narrative review","volume":"21","author":"Baas","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103275_bib48","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2741\/4324","article-title":"Gene therapy for hemophilia","volume":"20","author":"Rogers","year":"2015","journal-title":"Front Biosci (Landmark Ed)"},{"key":"10.1016\/j.rpth.2025.103275_bib49","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1182\/blood.2022018661","article-title":"Innovations in RNA therapy for hemophilia","volume":"142","author":"Ragni","year":"2023","journal-title":"Blood"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925005990?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925005990?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:57:14Z","timestamp":1778896634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037925005990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2475037925005990"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2025.103275","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health care resources and costs associated with delivering gene therapy for hemophilia in clinical practice","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2025.103275","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"103275"}}